Harm reduction is a set of practical strategies and ideas aimed at reducing negative consequences associated with drug use. It incorporates a spectrum of strategies, such as substituting one opioid for another (medication-assisted treatment — methadone, naltrexone, buprenorphine), or using an antidote (naloxone), or engaging in safer use (safe injection facilities), or abstinence. To ensure medication compliance, we have options, such as a monthly injection of naltrexone (Vivitrol), a monthly injection of buprenorphine (Sublocade), and a buprenorphine implant inserted in the upper arm that lasts 6 months (Probuphine). The FDA recently approved NSS-2 Bridge, a device mimicking a hearing aid, to help reduce opioid withdrawal symptoms. According to Vivek Murthy’s 2016 Surgeon General Report, which happens to be the first-ever Surgeon General’s Report on Alcohol, Drugs and Health, only about 10 percent of Americans with a drug use disorder obtain specialty treatment. The report attributes the low rate to severe shortages in the supply of care, which can lead to waiting periods of weeks or even months. Further, over 40 percent of people with a substance use disorder also have a mental health condition, yet fewer than half receive treatment for either disorder.